首页|Disulfiram:A novel repurposed drug for cancer therapy

Disulfiram:A novel repurposed drug for cancer therapy

扫码查看
Cancer is a major global health issue.Effective therapeutic strategies can prolong patients'survival and reduce the costs of treatment.Drug repurposing,which identifies new therapeutic uses for approved drugs,is a promising approach with the advantages of reducing research costs,shortening development time,and increasing efficiency and safety.Disulfiram(DSF),a Food and Drug Administration(FDA)-approved drug used to treat chronic alcoholism,has a great potential as an anticancer drug by targeting diverse human malignancies.Several studies show the antitumor effects of DSF,particularly the combination of DSF and copper(DSF/Cu),on a wide range of cancers such as glioblastoma(GBM),breast cancer,liver cancer,pancreatic cancer,and melanoma.In this review,we summarize the antitumor mechanisms of DSF/Cu,including induction of intracellular reactive oxygen species(ROS)and various cell death signaling pathways,and inhibition of proteasome activity,as well as inhibition of nuclear factor-kappa B(NF-κB)signaling.Furthermore,we highlight the ability of DSF/Cu to target cancer stem cells(CSCs),which provides a new approach to prevent tumor recurrence and metastasis.Strikingly,DSF/Cu inhibits several molecular targets associated with drug resistance,and therefore it is becoming a novel option to increase the sensitivity of chemo-resistant and radio-resistant patients.Studies of DSF/Cu may shed light on its improved application to clinical tumor treatment.

DisulfiramAldehyde dehydrogenaseReactive oxygen speciesProteasome activityCancer stem cellsDrug resistance

Min Zeng、Baibei Wu、Wenjie Wei、Zihan Jiang、Peiqiang Li、Yuanting Quan、Xiaobo Hu

展开 >

Department of Biochemistry and Molecular Biology,School of Basic Medicine,Hengyang Medical School,University of South China,Hengyang,Hunan 421001,China

The Key Laboratory of Ecological Environment and Critical Human Diseases Prevention of Hunan Province Department of Education,Hengyang Medical School,University of South China,Hengyang,Hunan 421001,China

institute of Biochemistry of Hengyang Medical School,University of South China,Hengyang,Hunan 421001,China

Undergraduate Research and Innovation Project of University of South ChinaUndergraduate Research and Innovation Project of University of South ChinaUndergraduate Research and Innovation Project of University of South China

X202110555528S202210555245X202210555136

2024

中华医学杂志(英文版)
中华医学会

中华医学杂志(英文版)

CSTPCD
影响因子:0.838
ISSN:0366-6999
年,卷(期):2024.137(12)